Clinical trials: Asthma, Bronchial
Asthma
Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma
This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment, crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose levels of Albuterol Sulfate Pressurized…
- Trial name
- NCT03364608
- Testing
- AS MDI 90 μg, AS MDI 180 µg, Proventil 90 μg
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- AstraZeneca
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Uncontrolled and Suspected Eosinophilic Asthma
A Phase IIa Study of KHK4563
This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma exacerbation rate in adult subjects with uncontrolled…
- Trial name
- 4563-003 (NCT01412736)
- Testing
- KHK4563
- Where
- 29 sites in Japan, South Korea
- Volunteers
- 106 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Asthma
Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult…
- Trial name
- NCT00073840
- Testing
- levalbuterol
- Where
- 54 sites in United States
- Volunteers
- 386 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)
The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo.
- Trial name
- NCT00163449
- Testing
- Ciclesonide
- Where
- 96 sites in Brazil, Germany and 7 more
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma
Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
The primary objective of this study is to compare the efficacy and safety of budesonide HFA MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler) 100 mcg 4 puffs BID in Chinese mild to moderate Asthma patients.
- Trial name
- NCT05152355
- Testing
- Budesonide 200 microgram/Puff, HFA MDI, Budesonide 100 microgram/Actuation Powder for Inhalation
- Where
- 13 sites in China
- Volunteers
- 270 people
- Sponsor
- Intech Biopharm Ltd.
Asthma
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg…
- Trial name
- TRIGGER (NCT02676089)
- Testing
- CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- Where
- 244 sites in Argentina, Belarus and 15 more
- Volunteers
- 1,437 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
- Trial name
- CAINAS SF (NCT01202097)
- Testing
- Salmeterol/Fluticasone, Seretide
- Where
- 6 sites in Brazil
- Volunteers
- 334 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma
A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma
GSK2245035 belongs to a novel class of agonist drugs targeted at toll like receptors (TLR). T-helper cell 2 (Th2) driven inflammation is a key patho-physiological mechanism in allergic asthma.
- Trial name
- NCT03707678
- Testing
- GSK2245035, FP-DPI, Albuterol/Salbutamol
- Sponsor
- GlaxoSmithKline
Asthma
Study In Asthma Control
This study will compare patients treated with a marketed medication and those who continue with their usual care to assess the proportion of patients achieving well controlled asthma after 24 weeks.
- Trial name
- NCT00273026
- Testing
- salmeterol xinafoate/fluticasone propionate
- Where
- 132 sites in Canada
- Volunteers
- 680 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- MM09-SIT-023 (NCT04435990)
- Testing
- 10,000 MM09, 30,000 MM09
- Where
- 32 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Inmunotek S.L.
Moderate/Severe Asthma
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period
- Trial name
- NCT00785733
- Where
- 44 sites in Romania
- Volunteers
- 1,182 people
- Sponsor
- AstraZeneca
Asthma
A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge
The purpose of this study is to find out how long the effect of PF-03526299 last after it is inhaled by assessing the lung function of mild asthma patients after they have been exposed to allergen
- Trial name
- NCT01299467
- Testing
- Active (PF-03526299)
- Sponsor
- Pfizer
Asthma
A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.
The clinical trial is designed to evaluate the non-inferiority of CHF1535 100/6 µg NEXThaler versus CHF1535 100/6 µg pMDI on the onset of relief from methacholine-induced bronchospasm, in terms of pulmonary function (i.e.
- Trial name
- NCT03108534
- Testing
- CHF1535 NEXThaler, CHF1535 pMDI
- Where
- 3 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Severe Asthma
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical…
- Trial name
- ANANKE (NCT04272463)
- Testing
- No intervention
- Where
- 18 sites in Italy
- Volunteers
- 217 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.
This study is a Phase 1, first in human (FiH) study, consisting of 3 parts (Part 1, Part 2, and Part 3) in healthy male and female participants of non-childbearing potential, performed at a single study center.
- Trial name
- NCT03436316
- Testing
- AZD8154
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Acute Otitis Media (AOM), Strep Pharyngitis
Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma
This study evaluates the diagnostic performance, usability, and clinical utility of the Medentum Diagnostik platform, a multisensor device with integrated software and artificial intelligence, in pediatric patients with asthma…
- Conditions
- Acute Otitis Media (AOM), Strep Pharyngitis, Asthma Exacerbation, Pediatric Asthma
- Trial name
- NCT07500532
- Testing
- Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis, Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation, Routine Asthma Management (in-person and telehealth visits)- Control Group
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Medentum Innovations
Asthma
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with…
- Trial name
- NCT01244984
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 30 sites in Japan
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.